Table 4.
The results of MMRM analyses: factors associated with EQ-VAS scores during follow-up
| Parameter | Parameter estimate | Standard error | P-value |
|---|---|---|---|
| Intercept | 18.371 | 5.498 | 0.001 |
| Age | −0.164 | 0.061 | 0.007 |
| Female (versus male) | −1.022 | 1.302 | 0.433 |
| Region (versus East Asia) | |||
| Mexico | −5.353 | 1.539 | 0.001 |
| The Middle East | −16.048 | 1.813 | <0.001 |
| Others | −8.566 | 4.161 | 0.040 |
| CGI-S score at baseline | 4.190 | 0.954 | <0.001 |
| EQ-VAS score at baseline | 0.733 | 0.025 | <0.001 |
| SSI-pain score at baseline | 0.237 | 0.129 | 0.068 |
| Comorbidities (versus none) | |||
| 1 | −4.181 | 1.680 | 0.013 |
| 2+ | −5.546 | 2.981 | 0.063 |
| Had MDD episodes in the 24 months prior to baseline | −1.071 | 1.328 | 0.420 |
| Duloxetine (versus SSRI) | 3.953 | 1.322 | 0.003 |
| Weeks (versus week 8) | |||
| Week 16 | 6.741 | 0.586 | <0.001 |
| Week 24 | 10.656 | 0.719 | <0.001 |
| Weeks × treat | |||
| Duloxetine at week 16 | 1.456 | 0.901 | 0.106 |
| Duloxetine at week 24 | 2.793 | 1.106 | 0.012 |
Abbreviations: EQ-VAS, EuroQoL-Visual Analog Scale; CGI-S, Clinical Global Impressions of Severity; SSRI, selective serotonin reuptake inhibitor; MMRM, mixed effects modeling with repeated measures; MDD, major depressive disorder; SSI-pain, somatic symptom inventory; QoL, quality of life.